The U.K. drugmaker GSK is seeking to expand regulatory approval for its new respiratory syncytial virus vaccine to include younger adults.
The U.K. drugmaker GSK is seeking to expand regulatory approval for its new respiratory syncytial virus vaccine to include younger adults, even as other manufacturers’ new RSV products face shortages across the U.S.
Analysts and executives say that uptake of the RSV vaccines for older adults from GSK and Pfizer has so far been strong, despite a lukewarm recommendation from the influential vaccines advisory committee of the Centers for Disease Control and Prevention. Over the long term, the high demand for RSV prophylactics points to the products developing into substantial blockbusters for these companies. GSK expects sales of its RSV shot Arexvy to peak at more than £3 billion, or $3.6 billion, while Pfizer has said it expects its shot Abrysvo to peak above $2 billion in annual sales.
For now, GSK is looking to expand its approval to allow younger adults to receive the shot. The company said Monday that early results from a new Phase 3 study show the immune responses elicited in adults aged 50 to 59 by the vaccine weren’t worse than those seen in adults aged 60 and above. GSK said it will be the “first company” to hand regulators data on that age group, and that approval could come next year.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
RSV Vaccine Shows Hopeful Early Results In 50 To 59-Year-Olds, GSK SaysI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »
RSV vaccine from GSK shows potential to protect adults 50 to 59The results suggest that GSK’s shot could help protect a wider population from RSV, which causes thousands of hospitalizations and deaths each year.
Read more »
RSV vaccine from GSK shows potential to protect adults 50 to 59The results suggest that GSK’s shot could help protect a wider population from RSV, which causes thousands of hospitalizations and deaths each year.
Read more »
Salt Lake-area companies face backlash amid payroll problemsEmployees at Forge Metals, a West Jordan-based company, were left without paychecks last week due to cash flow issues, according to a company statement.
Read more »
Power through your workouts on the cheap with the deeply discounted Skullcandy Push Active!Adrian, a mobile technology enthusiast since the Nokia 3310 era, has been a dynamic presence in the tech journalism field, contributing to Android Authority, Digital Trends, and Pocketnow before joining PhoneArena in 2018. His expertise spans across various platforms, with a particular fondness for the diversity of the Android ecosystem.
Read more »
Trump attorneys make new push to dismiss federal election subversion caseThey also asked a judge to strike any mention of the Jan. 6 Capitol attack from the indictment.
Read more »